Novartis

Novartis says its teams use AI-enhanced analytics to surface early risk signals across trial supply, monitoring and recruitment and to recommend next-best actions.

Novartis says generative AI can create well-structured first drafts of clinical and regulatory documents from approved sources, which Novartis experts then review and refine.

Novartis says that with generative approaches its teams can propose new molecular structures informed by protein information and prior chemistry and optimize multiple properties in parallel.

Cognizant says Novartis selected it for a five-year, AI-enabled integrated IT operations engagement using agentic AI.

Partners: Cognizant

Chai Discovery announced a collaboration giving Novartis access to Chai's AI models, including Chai-3, for antibody discovery across multiple targets.

Partners: Chai Discovery

Generate:Biomedicines announced a multi-target collaboration with Novartis using Generate's generative AI platform to discover protein therapeutics; Generate reports $65 million upfront consideration and potential value above $1 billion.

Partners: Generate:Biomedicines

Isomorphic Labs announced a strategic research collaboration with Novartis to discover small-molecule therapeutics against three undisclosed targets using Isomorphic's AI drug design platform.

Partners: Isomorphic Labs